Annual Report 2025

MANAGEMENT DISCUSSION AND ANALYSIS 17 The United Laboratories International Holdings Limited Annual Report 2025 Class I new drugs under development Project Category Indication Phase UBT251 Injection Chemical drug Overweight/Obesity Clinical trial UBT251 Injection Chemical drug Diabetes Clinical trial UBT251 Injection Chemical drug MASH Clinical trial UBT251 Injection Chemical drug Chronic kidney disease Clinical trial UBT251 Injection Chemical drug OSA Clinical trial UBT37034 for Injection Chemical drug Overweight/Obesity IND approved (United States) Clinical trial (PRC) UBT38006 Injection Biological drug Diabetes IND UBT48128 Oral Preparation Chemical drug Diabetes/Weight management Pre-clinical study Lp(a) Hypolipidemic Drug Chemical drug Hyperlipoproteinemia, atherosclerosis, aortic valve stenosis, etc. Pre-clinical study Interleukin-2 Fusion Protein Biological drug Vitiligo, alopecia areata, Pre-clinical study other autoimmune diseases UBT49003 Biological Drug Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS), etc. Pre-clinical study UBT506 Biological Drug Eczema, Asthma Pre-clinical study TUL01101 Tablets Chemical drug Rheumatoid arthritis Clinical trial TUL01101 Tablets Chemical drug Moderate to severe atopic dermatitis Clinical trial TUL01101 Ointment Chemical drug Atopic dermatitis Clinical trial TUL321 Capsules Chemical drug IgA nephropathy IND TUL12101 Eye Drops Chemical drug Xerophthalmia Clinical trial TUL108 for Injection Chemical drug Drug-resistant bacterial infection IND approved (United States) IND (PRC) LB2332 Chemical drug Fungal infection Pre-clinical study LB2249 Chemical drug Fat loss and muscle gain Pre-clinical study LB2237 Chemical drug Hyperlipidemia Pre-clinical study LB2343 Chemical drug Drug-resistant bacterial infection Pre-clinical study